ArticleFrontiers in immunology2026
Safety and immunogenicity of 13-Valent pneumococcal conjugate vaccine in healthy infants in Shanghai during the COVID-19 pandemic: a prospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Material and methods: A prospective cohort study was conducted from 2021 to 2023 in Shanghai. Cohort 1 (n=146) assessed immunogenicity and carriage, with infants receiving a 2 + 1 + 1 PCV13 series or no pneumococcal vaccine. Cohort 2 (n=114) assessed safety. Immunogenicity was assessed through serotype-specific IgG concentrations determined by ELISA, expressed as geometric mean concentrations (GMCs). Pneumococcal carriage was evaluated using nasopharyngeal swabs, with serotyping performed by multiplex real-time PCR. One-way repeated-measures ANOVA to compare the IgG GMCs in vaccinated group at three different time points. Results: In Cohort 1, 69.86% of vaccinated infants completed the 1-year follow-up. Carriage rates were 5.80% in the vaccinated group versus 6.45% in controls one month after the third dose (P = 1.00), and 3.92% versus 13.21% one year after the fourth dose (P = 0.161). IgG GMCs increased significantly from baseline to one month after the third dose (mean difference: 6.41 μg/mL, 95% CI: 5.43-7.39, P<0.001) and to one year after the fourth dose (mean difference: 12.01 μg/mL, 95% CI: 11.28-12.74, P<0.001). In Cohort 2, six infants reported mild adverse events, but no serious events or deaths were noted. Conclusion: PCV13 induced strong immunogenicity and showed a favorable safety profile, with a non-significant trend toward reduced pneumococcal carriage. These findings provide real-world evidence from Shanghai and support further evaluation of PCV13 in broader cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.